Dendritic Cell / Multiple Myeloma Fusion Vaccine
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 25 patients (estimated)
- Sponsors
- Beth Israel Deaconess Medical Center
- Collaborators
- Pfizer
- Tags
- Vaccine
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 2056
- NCT Identifier
- NCT06799026
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.